Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
1.980
-0.030 (-1.49%)
Apr 24, 2026, 4:00 PM EDT - Market closed
Acurx Pharmaceuticals Employees
Acurx Pharmaceuticals had 4 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,991,635
Market Cap
7.27M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2024 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2023 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2022 | 4 | 1 | 33.33% | 4 | 0 |
| Sep 30, 2022 | 4 | 1 | 33.33% | 4 | 0 |
| Dec 31, 2021 | 3 | 0 | - | 3 | 0 |
| Mar 31, 2021 | 3 | - | - | 2 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Genprex | 13 |
| Processa Pharmaceuticals | 12 |
| NuCana | 12 |
| MetaVia | 8 |
| TransCode Therapeutics | 7 |
| Immuron | 7 |
| Indaptus Therapeutics | 5 |
| Creative Medical Technology Holdings | 4 |
ACXP News
- 5 days ago - Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update - PRNewsWire
- 8 days ago - Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 9 days ago - Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 26 days ago - Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors - PRNewsWire
- 6 weeks ago - Acurx Pharmaceuticals Earnings Call Transcript: Q4 2025 - Transcripts
- 6 weeks ago - Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update - PRNewsWire
- 6 weeks ago - Why Is Acurx Pharmaceuticals Stock Up Over 105% Today? - Benzinga
- 6 weeks ago - Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection - PRNewsWire